Schisandrin B
Based on 12 publication(s) in Google Scholar
Schisandrin B (γ-Schisandrin) is a biphenylcyclooctadiene derivative isolated from Schisandra chinensis and has been shown to have antioxidant effects on the liver and heart of rodents.
Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.
- Pureté: 99.94%
- CAS No.: 61281-37-6
- Formule: C23H28O6
- Masse moléculaire:400.46
-
Stockage:Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 2 years , -20°C, 1 year
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Activité biologique
-
Chemical Information
-
Solvant et solubilité
- Pureté et documentation
- Références
-
Help & FAQs
-
Immunology/Inflammation Compound Library
HY-L007
-
Metabolism/Protease Compound Library
HY-L012
-
NF-κB Signaling Compound Library
HY-L014
-
Natural Product Library
HY-L021
-
Anti-Cancer Compound Library
HY-L025
-
Autophagy Compound Library
HY-L029
-
Anti-Aging Compound Library
HY-L034
-
Antioxidant Compound Library
HY-L037
-
Traditional Chinese Medicine Active Compound Library
HY-L065
-
Anti-Cancer Natural Product Library
HY-L107
-
Anti-inflammatory Traditional Chinese Medicine Active Compound Library
HY-L114
-
Plant-Sourced Natural Product Library
HY-L115
-
Human Metabolite Library
HY-L123
-
Cell Death Library
HY-L162
-
Radioprotector Library
HY-L178
-
Bioactive Compound Library Max
HY-L181
-
MCE Bioactive Compound Library
HY-L001V
-
Natural Product Library Plus
HY-L021P
-
Natural Product and Natural Product-Like Compound Library
HY-L021M
-
Bioactive Compound Library
HY-L001
-
Anti-Fibrosis Compound Library
HY-L185
-
RO5 Drug-like Natural Product Library
HY-L200
-
High-Throughput Bioactive Compound Library
HY-L205
-
High-Throughput Natural Product Library
HY-L206
-
Ancient Chinese Classical Formulas Traditional Chinese Medicine Active Compound Library
HY-L209
-
Mass Spectrometry Human Metabolite Library
HY-L215
-
Mongolian Medicine Compound Library
HY-L238
-
Lactylation Compound Library
HY-L249
-
Mass Spectrometry Natural Product Library
HY-L262
Publications Citing Use of MedChemExpress (MCE) Schisandrin B
More- Engineering. 2026 May 20.
- Biomater Sci. 2020 Jan 1;8(1):201-211. [Abstract]
- Eur J Pharmacol. 2019 Jul 15:855:10-19. [Abstract]
- Front Pharmacol. 2020 Jul 31;11:1175. [Abstract]
- Front Cell Dev Biol. 2021 Nov 10;9:763864. [Abstract]
- Tissue Eng Regen Med. 2023 Jun;20(3):447-459. [Abstract]
- Sci Rep. 2025 Feb 20;15(1):6200. [Abstract]
- Biochem Biophys Rep. 2026 Jan 15:45:102454. [Abstract]
- Toxicol In Vitro. 2024 May 22:105852. [Abstract]
- Oncologie. 2023 Mar 10.
- SSRN. 2025 Dec 27.
- bioRxiv. 2023 Aug 27.
Customer Validation & Images
-
WB
Activité biologique
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| HEK-293T | IC50 |
7.3 μM
Compound: 47
|
Inhibition of flag-tagged ATR expressed in HEK293T cells using PHAS-1 as substrate after 20 mins by autoradiography
Inhibition of flag-tagged ATR expressed in HEK293T cells using PHAS-1 as substrate after 20 mins by autoradiography
|
[PMID: 22835870] |
| HL60/ADR | IC50 |
0.5 ng/mL
Compound: Schisandrin B
|
TP_TRANSPORTER: inhibition of VCR transport in HL60/ADR cells (overexpression of MRP1)
TP_TRANSPORTER: inhibition of VCR transport in HL60/ADR cells (overexpression of MRP1)
|
[PMID: 17129588] |
| HL60/ADR | IC50 |
1676 ng/mL
Compound: Schisandrin B
|
TP_TRANSPORTER: inhibition of VP-16 transport in HL60/ADR cells (overexpression of MRP1)
TP_TRANSPORTER: inhibition of VP-16 transport in HL60/ADR cells (overexpression of MRP1)
|
[PMID: 17129588] |
| HL60/ADR | IC50 |
56 ng/mL
Compound: Schisandrin B
|
TP_TRANSPORTER: inhibition of DNR transport in HL60/ADR cells (overexpression of MRP1)
TP_TRANSPORTER: inhibition of DNR transport in HL60/ADR cells (overexpression of MRP1)
|
[PMID: 17129588] |
Schisandrin B modulates cellular redox status and activates Nrf2 and its dependent genes in lymphocytes[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:lymphocyte
-
Concentration:10-50 μM
-
Incubation Time:4 h
-
Result:Increase in relative mRNA copy number of Nrf2, HO-1, TrxR1, and GCLC.
Increased basal ROS levels and decreased GSH/GSSG ratio.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Mice endotoxic shock model[1]
-
Dosage:80 mg/kg
-
Administration:Intraperitoneally injected (i.p.), single dose
-
Result:Decreased proliferation and secretion of the proinflammatory cytokines IL-2, IL-6, and IFN-g .
Chemical Information
-
CAS No. 61281-37-6
-
Appearance Solid
-
Masse moléculaire 400.46
-
Formule C23H28O6
-
Color White to off-white
-
SMILES
CC(C1)C(C)CC2=CC(OC)=C(OC)C(OC)=C2C3=C1C=C4OCOC4=C3OC
-
Synonyms
γ-Schisandrin; Wuweizisu B
-
Structure Classification
-
Initial Source
-
Livraison
Room temperature in continental US; may vary elsewhere.
-
Stockage
Powder -20°C 3 years 4°C 2 years In solvent -80°C 2 years -20°C 1 year
Publications (12)
-
Journal Impact Factor
-
Most Recent
-
-
Biomater Sci
Polyethyleneimine coated Fe3O4 magnetic nanoparticles induce autophagy, NF-κB and TGF-β signaling pathway activation in HeLa cervical carcinoma cells via reactive oxygen species generation. [Abstract]2020 Jan 1;8(1):201-211. PMID: 31664285 -
Eur J Pharmacol
Schizandrin A enhances the efficacy of gefitinib by suppressing IKKβ/NF-κB signaling in non-small cell lung cancer. [Abstract]2019 Jul 15:855:10-19. PMID: 31028739 -
Front Pharmacol
Schisandrin B Inhibits Osteoclastogenesis and Protects Against Ovariectomy-Induced Bone Loss. [Abstract]2020 Jul 31;11:1175. PMID: 32848781
Schisandrin B purchased from MedChemExpress. Usage Cited in: Front Pharmacol. 2020 Jul 31;11:1175. [Abstract]
BMMs are cultured with or without 20 μM Schisandrin B in the presence of M-CSF and RANKL for the indicated time periods. The inhibitory effects of Schisandrin B on osteoclast-related genes expression are further confirmed by Western blot analysis, which shows that Schisandrin B dramatically suppresses the protein expression of these target genes during osteoclast differentiation.
-
Front Cell Dev Biol
Curdione and Schisandrin C Synergistically Reverse Hepatic Fibrosis via Modulating the TGF-β Pathway and Inhibiting Oxidative Stress. [Abstract]2021 Nov 10;9:763864. PMID: 34858986 -
Tissue Eng Regen Med
Schisandrin B Improves the Hypothermic Preservation of Celsior Solution in Human Umbilical Cord Mesenchymal Stem Cells. [Abstract]2023 Jun;20(3):447-459. PMID: 36947320 -
Sci Rep
In vivo and in vitro investigations of schisandrin B against angiotensin II induced ferroptosis and atrial fibrosis by regulation of the SIRT1 pathway. [Abstract]2025 Feb 20;15(1):6200. PMID: 39979353 -
Biochem Biophys Rep
2026 Jan 15:45:102454. PMID: 41584303 -
Toxicol In Vitro
Schisandrin B protect inner hair cells from cisplatin by inhibiting celluar oxidative stress and apoptosis. [Abstract]2024 May 22:105852. PMID: 38789064 -
-
-
Solvant et solubilité
DMSO : 100 mg/mL (249.71 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.5 mg/mL (6.24 mM); Clear solution
This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 2.5 mg/mL (6.24 mM); Clear solution
This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL.
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Pureté et documentation
-
Fiche technique (284 KB)
-
SDS (396 KB)
- English - EN (396 KB)
- Français - FR (396 KB)
- Deutsch - DE (396 KB)
- Norwegian - NO (396 KB)
- Español - ES (396 KB)
- Swedish - SV (396 KB)
- Italian - IT (396 KB)
- Korean - KR (396 KB)
- Portuguese - PT (396 KB)
-
Instruction de manipulation (2659 KB)
Références
[1]. Checker R, et al. Schisandrin B exhibits anti-inflammatory activity through modulation of the redox-sensitive transcription factors Nrf2 and NF-κB. Free Radic Biol Med. 2012 Oct 1;53(7):1421-30. [Content Brief]
[2]. Lam PY, et al. Schisandrin B as a hormetic agent for preventing age-related neurodegenerative diseases. Oxid Med Cell Longev. 2012;2012:250825. [Content Brief]
[3]. Zeng KW, et al. Schisandrin B exerts anti-neuroinflammatory activity by inhibiting the Toll-like receptor 4-dependent MyD88/IKK/NF-κB signaling pathway in lipopolysaccharide-induced microglia. Eur J Pharmacol. 2012 Oct 5;692(1-3):29-37. [Content Brief]
[4]. Liu Z, et al. Schisandrin B attenuates cancer invasion and metastasis via inhibiting epithelial-mesenchymal transition. PLoS One. 2012;7(7):e40480. [Content Brief]
[5]. Zhu S, et al. Protective effect of schisandrin B against cyclosporine A-induced nephrotoxicity in vitro and in vivo. Am J Chin Med. 2012;40(3):551-66. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 2.4971 mL | 12.4856 mL | 24.9713 mL | 62.4282 mL |
| 5 mM | 0.4994 mL | 2.4971 mL | 4.9943 mL | 12.4856 mL | |
| 10 mM | 0.2497 mL | 1.2486 mL | 2.4971 mL | 6.2428 mL | |
| 15 mM | 0.1665 mL | 0.8324 mL | 1.6648 mL | 4.1619 mL | |
| 20 mM | 0.1249 mL | 0.6243 mL | 1.2486 mL | 3.1214 mL | |
| 25 mM | 0.0999 mL | 0.4994 mL | 0.9989 mL | 2.4971 mL | |
| 30 mM | 0.0832 mL | 0.4162 mL | 0.8324 mL | 2.0809 mL | |
| 40 mM | 0.0624 mL | 0.3121 mL | 0.6243 mL | 1.5607 mL | |
| 50 mM | 0.0499 mL | 0.2497 mL | 0.4994 mL | 1.2486 mL | |
| 60 mM | 0.0416 mL | 0.2081 mL | 0.4162 mL | 1.0405 mL | |
| 80 mM | 0.0312 mL | 0.1561 mL | 0.3121 mL | 0.7804 mL | |
| 100 mM | 0.0250 mL | 0.1249 mL | 0.2497 mL | 0.6243 mL |
Schisandrin B Related Classifications
HY-N0089 Related Classifications
Powered by Bioz